The economic impact of tacrine in the treatment of Alzheimer's disease

Clinical Therapeutics

Volumn 19, Issue 2, 1997, Pages 330-345

  Henke, Curtis J ^a   Burchmore, Michael J ^a  

^a Technology Assessment Group   (United States)

Author keywords

Alzheimer's disease; pharmacoeconomics; tacrine

Indexed keywords

TACRINE;

AGED; ALZHEIMER DISEASE; COST CONTROL; DECISION MAKING; DRUG COST; FOLLOW UP; HUMAN; MEDICAL SERVICE; NURSING HOME; QUALITY OF LIFE; REVIEW; SOCIAL WORK;

EID: 0030927301     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80121-X     Document Type: Article

References (21)

1. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: Study methods and prevalence of dementia. Can Med Assoc J. 1994; 150:899-913.
2. Knopman D. Tacrine for Alzheimer's disease. PharmacoEconomics. 1995;7:275-279.
3. Evans DA, Scherr PA, Cook NR, et al. Estimated prevalence of Alzheimer's disease in the United States. Milbank Q. 1990;68:267-289.
4. Boykin A, Winland-Brown J. The dark side of caring. J Gerontol Nurs. 1995;21: 13-18.
5. Collins C, Stommel M. Out of pocket expenditures by family caregivers of dementia patients residing in the community. Home Health Care Serv Q. 1991; 12:29-43.
6. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84: 1261-1264.
7. Hu T, Huang L, Cartwright WS. Evaluation of the costs of caring for the senile demented elderly: A pilot study. Gerontologist. 1986;26:158-163.
8. Huang L-F, Cartwright WS, Hu T-W. The economic cost of senile dementia in the United States, 1985. Public Health Rep. 1988;103:3-7.
9. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff. 1993;12:164-176.
10. Hay JW, Ernst RL. The economic costs of Alzheimer's disease. Am J Public Health. 1987;77:1169-1175.
11. Ostbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J. 1994;151:1457-1464.
12. Lubeck DP, Mazonson PD, Bowe T. Potential effect of tacrine on expenditures for Alzheimer's disease. Med Interface. 1994;7:130-138.
13. Knapp MJ, Knopman DS, Solomon PS, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994;271: 985-991.
14. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex®) treatment: Effects on nursing home placement and mortality. Neurology. 1996;47:166-177.
15. Severson MA, Smith GL, Tangalos EG, et al. Patterns and predictors of institutionalization in community-based dementia patients. J Am Geriatr Soc. 1994;42: 181-185.
16. Welch HG, Walsh JS, Larson EB. The cost of institutional care in Alzheimer's disease: Nursing home and hospital use in a prospective cohort. J Am Geriatr Soc. 1992;40:221-224.
17. Cowan CA, Letsch SW, Levit KR, et al. Health care indicators. Health Care Financ Rev. 1991;12:121-140.
18. Sensing AL, Heffler SK, Donham CS. Health care indicators. Health Care Financ Rev. 1995;17:277-317.
19. 1994 Red Book®. Montvale, NJ: Medical Economics Data, Inc; 1994.
20. HCIA Inc. and Arthur Anderson and Company. The Guide to Nursing Home Industry. Baltimore, Md: Healthcare Investment Analysts Inc; 1993.
21. Bergman-Evans B. A health profile of spousal Alzheimer's caregivers. J Psychosoc Nurs. 1994;32:25-30.